Natera, Inc. (NTRA)
USD 132.23
(-4.36%)
USD 132.23
(-4.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.08 Billion USD | 31.99% |
| 2022 | 820.22 Million USD | 31.13% |
| 2021 | 625.48 Million USD | 59.97% |
| 2020 | 391 Million USD | 29.33% |
| 2019 | 302.32 Million USD | 17.34% |
| 2018 | 257.65 Million USD | 22.15% |
| 2017 | 210.93 Million USD | -2.83% |
| 2016 | 217.07 Million USD | 14.04% |
| 2015 | 190.35 Million USD | 19.5% |
| 2014 | 159.28 Million USD | 188.72% |
| 2013 | 55.17 Million USD | 287.16% |
| 2012 | 14.25 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 367.74 Million USD | 18.2% |
| 2024 Q2 | 413.35 Million USD | 12.4% |
| 2023 Q2 | 261.4 Million USD | 8.13% |
| 2023 Q1 | 241.75 Million USD | 11.28% |
| 2023 FY | 1.08 Billion USD | 31.99% |
| 2023 Q4 | 311.1 Million USD | 15.95% |
| 2023 Q3 | 268.3 Million USD | 2.64% |
| 2022 Q2 | 198.2 Million USD | 2.09% |
| 2022 Q3 | 210.63 Million USD | 6.27% |
| 2022 Q4 | 217.25 Million USD | 3.14% |
| 2022 FY | 820.22 Million USD | 31.13% |
| 2022 Q1 | 194.13 Million USD | 12.2% |
| 2021 Q2 | 142.02 Million USD | -6.76% |
| 2021 Q4 | 173.02 Million USD | 9.43% |
| 2021 FY | 625.48 Million USD | 59.97% |
| 2021 Q3 | 158.11 Million USD | 11.33% |
| 2021 Q1 | 152.31 Million USD | 35.54% |
| 2020 Q3 | 98.14 Million USD | 13.5% |
| 2020 Q4 | 112.37 Million USD | 14.5% |
| 2020 FY | 391 Million USD | 29.33% |
| 2020 Q1 | 94.01 Million USD | 12.94% |
| 2020 Q2 | 86.47 Million USD | -8.02% |
| 2019 Q3 | 77.9 Million USD | 4.78% |
| 2019 FY | 302.32 Million USD | 17.34% |
| 2019 Q4 | 83.24 Million USD | 6.84% |
| 2019 Q1 | 66.82 Million USD | -0.21% |
| 2019 Q2 | 74.35 Million USD | 11.27% |
| 2018 Q1 | 62.34 Million USD | 15.95% |
| 2018 Q3 | 65.28 Million USD | 3.51% |
| 2018 Q4 | 66.96 Million USD | 2.58% |
| 2018 FY | 257.65 Million USD | 22.15% |
| 2018 Q2 | 63.06 Million USD | 1.17% |
| 2017 Q1 | 46.9 Million USD | -4.86% |
| 2017 Q4 | 53.76 Million USD | -5.1% |
| 2017 FY | 210.93 Million USD | -2.83% |
| 2017 Q3 | 56.65 Million USD | 5.67% |
| 2017 Q2 | 53.61 Million USD | 14.32% |
| 2016 Q1 | 61.9 Million USD | 16.99% |
| 2016 FY | 217.07 Million USD | 14.04% |
| 2016 Q4 | 49.29 Million USD | -8.52% |
| 2016 Q3 | 53.88 Million USD | 3.66% |
| 2016 Q2 | 51.98 Million USD | -16.02% |
| 2015 Q1 | 47.43 Million USD | -4.91% |
| 2015 Q3 | 44.92 Million USD | -0.37% |
| 2015 FY | 190.35 Million USD | 19.5% |
| 2015 Q4 | 52.91 Million USD | 17.79% |
| 2015 Q2 | 45.08 Million USD | -4.95% |
| 2014 Q2 | 35.83 Million USD | 31.29% |
| 2014 Q3 | 46.27 Million USD | 29.13% |
| 2014 Q4 | 49.88 Million USD | 7.8% |
| 2014 FY | 159.28 Million USD | 188.72% |
| 2014 Q1 | 27.29 Million USD | 17.45% |
| 2013 Q4 | 23.24 Million USD | 43.29% |
| 2013 Q1 | 4.64 Million USD | 0.0% |
| 2013 FY | 55.17 Million USD | 287.16% |
| 2013 Q3 | 16.21 Million USD | 0.0% |
| 2012 FY | 14.25 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -3364.338% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | -7998.565% |
| Aspira Women's Health Inc. | 9.15 Million USD | -11726.207% |
| Biodesix, Inc. | 49.08 Million USD | -2105.413% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | -10979.649% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -42647.144% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | -42647.144% |
| Bionano Genomics, Inc. | 36.11 Million USD | -2897.483% |
| CareDx, Inc | 280.32 Million USD | -286.186% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Castle Biosciences, Inc. | 219.78 Million USD | -392.552% |
| DarioHealth Corp. | 20.35 Million USD | -5219.236% |
| Exact Sciences Corporation | 2.49 Billion USD | 56.693% |
| Fulgent Genetics, Inc. | 289.21 Million USD | -274.316% |
| Guardant Health, Inc. | 563.94 Million USD | -91.963% |
| ICON Public Limited Company | 8.12 Billion USD | 86.668% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 70.429% |
| Illumina, Inc. | 4.5 Billion USD | 75.964% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | -34689.434% |
| iSpecimen Inc. | 9.92 Million USD | -10804.018% |
| Standard BioTools Inc. | 106.34 Million USD | -918.028% |
| MDxHealth SA | 70.19 Million USD | -1442.278% |
| 23andMe Holding Co. | 219.63 Million USD | -392.889% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 42.595% |
| Myriad Genetics, Inc. | 678.4 Million USD | -59.577% |
| Mainz Biomed B.V. | 895.47 Thousand USD | -120792.952% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| NeoGenomics, Inc. | 591.64 Million USD | -82.977% |
| Neogen Corporation | 924.22 Million USD | -17.133% |
| Inotiv, Inc. | 572.42 Million USD | -89.12% |
| OpGen, Inc. | 3.41 Million USD | -31569.68% |
| OPKO Health, Inc. | 863.49 Million USD | -25.371% |
| Psychemedics Corporation | 22.09 Million USD | -4798.955% |
| Prenetics Global Limited | 21.74 Million USD | -4879.015% |
| Prenetics Global Limited | 21.74 Million USD | -4879.015% |
| Precipio, Inc. | 15.19 Million USD | -7023.584% |
| Personalis, Inc. | 73.48 Million USD | -1373.267% |
| RadNet, Inc. | 1.61 Billion USD | 33.035% |
| Sera Prognostics, Inc. | 306 Thousand USD | -353681.373% |
| Sotera Health Company | 1.04 Billion USD | -3.172% |
| Neuronetics, Inc. | 71.34 Million USD | -1417.311% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -2264.467% |
| Star Equity Holdings, Inc. | 45.78 Million USD | -2264.467% |
| Trinity Biotech plc | 56.83 Million USD | -1804.862% |
| T2 Biosystems, Inc. | 7.19 Million USD | -14950.341% |
| Twist Bioscience Corporation | 312.97 Million USD | -245.898% |
| Exagen Inc. | 52.54 Million USD | -1960.156% |